← Back to screener

Jazz Pharmaceuticals plc JAZZ

Rank #1230 · Nasdaq · $13.6B market cap
Audited by KPMG, no going-concern flag in the latest filing.
Score
51.5
P/E
32.7
P/B
4.39
ROE
13.4%
Op. Margin
15.1%
Debt Ratio
289%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E 32.7x, P/B 4.39x. Ranks in the top 52% of the universe.

Profitability ★★★☆☆
Good

ROE 13.4%. Ranks in the top 32% of the universe.

Safety ★☆☆☆☆
Weak

Debt ratio 289%. Ranks in the top 71% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★☆☆☆
Average

Revenue growth of 4.8% year over year. Ranks in the top 50% of the universe.

Profitability is the relative strength · Safety is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011$0.1B$0.0B$-0.0B$-0.1B12.4-246
2012$0.2B$0.1B$0.0B$-0.1B33.3-448
2013$0.3B$0.1B$0.1B$0.0B46.96337
2014$0.6B$0.2B$0.3B$1.3B33.873
2015$0.9B$0.3B$0.2B$1.4B39.0144
2016$1.2B$0.2B$0.1B$1.3B16.7157
2017$1.3B$0.5B$0.3B$1.9B38.4156
2018$1.5B$0.6B$0.4B$2.7B39.889
2019$1.6B$0.5B$0.5B$1.9B32.7177
2020$1.9B$0.6B$0.4B$2.7B32.5104
2021$2.2B$0.5B$0.5B$2.8B24.6137
2022$2.4B$0.4B$0.2B$3.1B16.0295
2023$3.1B$0.2B$-0.3B$3.7B5.5196
2024$3.7B$-0.1B$-0.2B$4.0B-1.8187
2025$3.8B$0.6B$0.4B$3.1B15.1289

← See the full screener